Cash from Financing (Quarterly) Chart

View Cash from Financing (Quarterly) for IFRX.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Cash from Financing (Quarterly) Chart
Start Trial

Historical Cash from Financing (Quarterly) Data

View and export this data back to 2017. Start Trial.
Date Value
June 30, 2026 138.70M
March 31, 2026 -0.0874M
September 30, 2025 0.8472M
June 30, 2025 2.075M
March 31, 2025 28.43M
September 30, 2024 -0.1109M
June 30, 2024 -0.1148M
March 31, 2024 -0.093M
December 31, 2023 -0.7612M
September 30, 2023 -0.1294M
June 30, 2023 57.84M
March 31, 2023 0.0324M
December 31, 2022 2.251M
September 30, 2022 -0.0812M
June 30, 2022 -0.0918M
March 31, 2022 -0.1019M
December 31, 2021 -2.244M
Date Value
September 30, 2021 -1.764M
June 30, 2021 -0.0409M
March 31, 2021 74.43M
December 31, 2020 0.1084M
September 30, 2020 10.48M
June 30, 2020 0.442M
March 31, 2020 -0.0973M
December 31, 2019 -0.0952M
September 30, 2019 -0.0902M
June 30, 2019 -0.078M
March 31, 2019 -0.0625M
December 31, 2018 -1.094M
September 30, 2018 -0.8388M
June 30, 2018 58.58M
March 31, 2018 0.00
December 31, 2017 126.33M
September 30, 2017 0.11M

Cash From Financing Definition

Represents the net cash flow resulting from the company's financing activities. Financing activities represent movement in the company's debt and share capital and other activities.

Read full definition.

Cash from Financing (Quarterly) Range, Past 5 Years

View Cash from Financing (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Cash from Financing (Quarterly) Benchmarks

View Cash from Financing (Quarterly) Benchmarks
Start Trial
MediGene AG --
BioNTech SE -126.88M
Immatics NV -0.9257M
Beam Therapeutics, Inc. 7.523M
Kymera Therapeutics, Inc. 14.42M